title: Impact of chronic oral anticoagulation on management and outcomes of patients with acute myocardial infarction: data from the RICO survey.
abstract: OBJECTIVE
  To determine the prevalence of chronic oral anticoagulant drug treatment (COA) among patients with acute myocardial infarction (AMI) and its impact on management and outcome.
  
  
  METHODS
  All patients with ST segment elevation AMI on the RICO (a French regional survey for AMI) database were included in this analysis. COA was defined as continuous use >or= 48 hours before AMI.
  
  
  RESULTS
  Among the 2112 patients with ST elevation myocardial infarction (STEMI), 93 (4%) patients were receiving COA. These patients were older and more likely to have a history of hypertension, diabetes and prior myocardial infarction than patients without COA. In addition, fewer patients who received COA underwent reperfusion therapy or received an antiplatelet agent (aspirin/thienopyridines). Moreover, patients receiving COA experienced a higher incidence of in-hospital major adverse events (death, recurrent myocardial infarction or major bleeding, p = 0.005). Multivariate analysis showed that only ejection fraction, current smoking and multiple vessel disease, but not COA, were independent predictive factors for major adverse events. In contrast, COA was an independent predictive factor for heart failure when adjusted for age, diabetes, creatinine clearance, reperfusion, heparin and glycoprotein IIb/IIIa inhibitors (odds ratio 2.06, CI 95% 1.23 to 3.43, p = 0.005).
  
  
  CONCLUSIONS
  In this population based registry, patients with STEMI with prior use of COA constituted a fairly large group (4%) with an overall higher baseline risk profile than that of patients without COA. Fewer in the COA group received reperfusion therapy or aggressive antithrombotic treatment and they experienced more adverse in-hospital outcomes. Thus, further studies are warranted to develop specific management strategies for this high risk group.
authors.affiliation: Service de Cardiologie, CHU Bocage, Dijon, France.
authors.forename: A
authors.initials: A
authors.lastname: Oudot
authors.forename: P G
authors.initials: PG
authors.lastname: Steg
authors.forename: N
authors.initials: N
authors.lastname: Danchin
authors.forename: G
authors.initials: G
authors.lastname: Dentan
authors.forename: M
authors.initials: M
authors.lastname: Zeller
authors.forename: P
authors.initials: P
authors.lastname: Sicard
authors.forename: P
authors.initials: P
authors.lastname: Buffet
authors.forename: Y
authors.initials: Y
authors.lastname: Laurent
authors.forename: L
authors.initials: L
authors.lastname: Janin-Manificat
authors.forename: I
authors.initials: I
authors.lastname: L'Huillier
authors.forename: J C
authors.initials: JC
authors.lastname: Beer
authors.forename: H
authors.initials: H
authors.lastname: Makki
authors.forename: P
authors.initials: P
authors.lastname: Morel
authors.forename: Y
authors.initials: Y
authors.lastname: Cottin
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000453:epidemiology; D015425:Myocardial Reperfusion / Q000706:statistics & numerical data; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015995:Prevalence; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors